{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:20:40Z","timestamp":1785853240371,"version":"3.56.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,8,31]],"date-time":"2005-08-31T00:00:00Z","timestamp":1125446400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00198-005-1986-1","type":"journal-article","created":{"date-parts":[[2005,8,30]],"date-time":"2005-08-30T12:08:18Z","timestamp":1125403698000},"page":"1989-1998","source":"Crossref","is-referenced-by-count":26,"title":["Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England"],"prefix":"10.1007","volume":"16","author":[{"given":"Beate Aurich","family":"Barrera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Wilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad A. W.","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,8,31]]},"reference":[{"key":"1986_CR1","unstructured":"Summary of product characteristics (2000) Actonel 5\u00a0mg. Procter and Gamble Pharmaceuticals UK, pp 1\u20138"},{"key":"1986_CR2","unstructured":"Summary of product characteristics (2000), Actonel 30\u00a0mg. Procter and Gamble Pharmaceuticals UK, 1\u20136"},{"key":"1986_CR3","unstructured":"Summary of product characteristics (2003), Actonel once a week 35\u00a0mg. Procter and Gamble Pharmaceuticals UK"},{"key":"1986_CR4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s11926-003-0085-6","volume":"5","author":"Reszka","year":"2003","unstructured":"Reszka AA, Rodan GA (2003) Bisphosphonate mechanism of action. Curr Rheumatol Rep 5(1):65\u201374","journal-title":"Curr Rheumatol Rep"},{"key":"1986_CR5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333\u2013340","journal-title":"N Engl J Med"},{"key":"1986_CR6","first-page":"1895","volume":"85","author":"Fogelman","year":"2000","unstructured":"Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab 85(5):1895\u20131900","journal-title":"J Clin Endocrinol Metab"},{"key":"1986_CR7","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"Reginster","year":"2000","unstructured":"Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83\u201391","journal-title":"Osteoporos Int"},{"key":"1986_CR8","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344\u20131352","journal-title":"JAMA"},{"key":"1986_CR9","first-page":"396","volume":"83","author":"Mortensen","year":"1998","unstructured":"Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC Jr (1998) Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83(2):396\u2013402","journal-title":"J Clin Endocrinol Metab"},{"key":"1986_CR10","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1007\/PL00004152","volume":"7","author":"Clemmesen","year":"1997","unstructured":"Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY (1997) A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis. Osteoporos Int 7(5):488\u2013495","journal-title":"Osteoporos Int"},{"key":"1986_CR11","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1210\/er.2001-3002","volume":"23","author":"Cranney","year":"2002","unstructured":"Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson V, Shea B, Wells G, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocr Rev 23(4):517\u2013523","journal-title":"Endocr Rev"},{"key":"1986_CR12","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(99)00062-5","volume":"106","author":"Miller","year":"1999","unstructured":"Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget\u2019s disease of bone. Paget\u2019s Risedronate\/Etidronate Study Group. Am J Med 106(5):513\u2013520","journal-title":"Am J Med"},{"key":"1986_CR13","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s002239900584","volume":"64","author":"Brown","year":"1999","unstructured":"Brown JP, Hosking DJ, Ste-Marie L, Johnston CC Jr, Reginster J, Ryan WG, Johnson TD, Bekker PJ (1999) Risedronate, a highly effective, short-term oral treatment for Paget\u2019s disease: a dose-response study. Calcif Tissue Int 64(2):93\u201399","journal-title":"Calcif Tissue Int"},{"key":"1986_CR14","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S8756-3282(99)00271-9","volume":"26","author":"Brown","year":"2000","unstructured":"Brown JP, Chines AA, Myers WR, Eusebio RA, Ritter-Hrncirik C, Hayes CW (2000) Improvement of pagetic bone lesions with risedronate treatment: a radiologic study. Bone 26(3):263\u2013267","journal-title":"Bone"},{"key":"1986_CR15","unstructured":"The Royal College of Physicians, The Bone and Tooth Society of Great Britain, The National Osteoporosis Society (2002) Management of glucocorticoid-induced osteoporosis\u2014Guidelines for prevention and treatment. Royal College of Physicians of London, London, pp 1\u201357"},{"key":"1986_CR16","unstructured":"Anonymous (2001) Drugs affecting bone metabolism. In: Mehta DK (ed) British National Formulary. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, pp 359\u2013362"},{"key":"1986_CR17","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s00223-001-1060-8","volume":"69","author":"Reid","year":"2001","unstructured":"Reid DM, Adami S, Devogelaer JP, Chines AA (2001) Risedronate increases bone density and reduces vertebral fracture risk within 1 year in men on corticosteroid therapy. Calcif Tissue Int 69(4):242\u2013247","journal-title":"Calcif Tissue Int"},{"key":"1986_CR18","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s002230001146","volume":"67","author":"Wallach","year":"2000","unstructured":"Wallach S, Cohen S, Reid DM, Hughes RA, Hosking DJ, Laan RF, Doherty SM, Maricic M, Rosen C, Brown J, Barton I, Chines AA (2000) Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 67(4):277\u2013285","journal-title":"Calcif Tissue Int"},{"key":"1986_CR19","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s001980070122","volume":"11","author":"Eastell","year":"2000","unstructured":"Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Nagant D, Russell RG (2000) Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int 11(4):331\u2013337","journal-title":"Osteoporos Int"},{"key":"1986_CR20","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1359\/jbmr.2000.15.6.1006","volume":"15","author":"Reid","year":"2000","unstructured":"Reid DM, Hughes RA, Laan RF, Sacco-Gibson NA, Wenderoth DH, Adami S, Eusebio RA, Devogelaer JP (2000) Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J Bone Miner Res 15(6):1006\u20131013","journal-title":"J Bone Miner Res"},{"key":"1986_CR21","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/1529-0131(199911)42:11<2309::AID-ANR8>3.0.CO;2-K","volume":"42","author":"Cohen","year":"1999","unstructured":"Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, Zizic TM, Wallach S, Sewell KL, Lukert BP, Axelrod DW, Chines AA (1999) Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 42(11):2309\u20132318","journal-title":"Arthritis Rheum"},{"key":"1986_CR22","first-page":"2949","volume":"60","author":"Boissier","year":"2000","unstructured":"Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaisse JM, Clezardin P (2000) Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 60(11):2949\u20132954","journal-title":"Cancer Res"},{"key":"1986_CR23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00002281-200307000-00014","volume":"15","author":"Reid","year":"2003","unstructured":"Reid IR (2003) Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 15(4):458\u2013463","journal-title":"Curr Opin Rheumatol"},{"key":"1986_CR24","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0149-2918(01)80065-5","volume":"23","author":"Drake","year":"2001","unstructured":"Drake WM, Kendler DL, Brown JP (2001) Consensus statement on the modern therapy of Paget\u2019s disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9\u201310, 2000. Clin Ther 23(4):620\u2013626","journal-title":"Clin Ther"},{"key":"1986_CR25","first-page":"1965","volume":"29","author":"Thomson","year":"2002","unstructured":"Thomson AB, Marshall JK, Hunt RH, Provenza JM, Lanza FL, Royer MG, Li Z, Blank MA (2002) 14\u00a0day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status. J Rheumatol 29(9):1965\u20131974","journal-title":"J Rheumatol"},{"key":"1986_CR26","doi-asserted-by":"crossref","first-page":"262","DOI":"10.4065\/77.3.262","volume":"77","author":"Taggart","year":"2002","unstructured":"Taggart H, Bolognese MA, Lindsay R, Ettinger MP, Mulder H, Josse RG, Roberts A, Zippel H, Adami S, Ernst TF, Stevens KP (2002) Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials. Mayo Clin Proc 77(3):262\u2013270","journal-title":"Mayo Clin Proc"},{"key":"1986_CR27","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1046\/j.1365-2036.2000.00887.x","volume":"14","author":"Lanza","year":"2000","unstructured":"Lanza FL, Rack MF, Li Z, Krajewski SA, Blank MA (2000) Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs aspirin in healthy postmenopausal women. Aliment Pharmacol Ther 14(12):1663\u20131670","journal-title":"Aliment Pharmacol Ther"},{"key":"1986_CR28","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1111\/j.1572-0241.2000.03258.x","volume":"95","author":"Lanza","year":"2000","unstructured":"Lanza FL, Schwartz H, Sahba B, Malaty HM, Musliner T, Reyes R, Quan H, Graham DY (2000) An endoscopic comparison of the effects of alendronate and risedronate on upper-gastrointestinal mucosae. Am J Gastroenterol 95(11):3112\u20133117","journal-title":"Am J Gastroenterol"},{"key":"1986_CR29","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","volume":"119","author":"Lanza","year":"2000","unstructured":"Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA (2000) Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 119(3):631\u2013638","journal-title":"Gastroenterology"},{"key":"1986_CR30","first-page":"598","volume":"Clin","author":"Vinas","year":"2002","unstructured":"Vinas G, Olive A, Holgado S, Costa J (2002) Episcleritis secondary to risedronate. Med Clin (Barc) 118(15):598\u2013599","journal-title":"Med"},{"key":"1986_CR31","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0002-9394(02)01840-8","volume":"135","author":"Fraunfelder","year":"2003","unstructured":"Fraunfelder FW, Fraunfelder FT, Jensvold B (2003) Scleritis and other ocular side effects associated with pamidronate disodium. Am J Ophthalmol 135 (2):219\u2013222","journal-title":"Am J Ophthalmol"},{"key":"1986_CR32","first-page":"337","volume":"67","author":"Rey","year":"2000","unstructured":"Rey J, Daumen-Legre V, Pham T, Bernard P, Dahan L, Acquaviva P, Lafforgue P (2000) Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review. Joint Bone Spine 67(4):337\u2013340","journal-title":"Joint Bone Spine"},{"key":"1986_CR33","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/j.1742-1241.1995.tb09976.x","volume":"49","author":"O","year":"1995","unstructured":"O\u2019Donnell N, Rao GP, Aguis-Fernandez A (1995) Paget\u2019s disease: Ocular complications of disodium pamidronate treatment. Br J Clin Pract 49 (5):272\u2013273","journal-title":"Br J Clin Pract"},{"key":"1986_CR34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/rheumatology\/34.5.479","volume":"34","author":"De","year":"1995","unstructured":"De S, Meyer P, Crisp AJ (1995) Pamidronate and Uveitis. Br J Rheumatol 34(5):479","journal-title":"Br J Rheumatol"},{"key":"1986_CR35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S0002-9394(14)72902-2","volume":"118","author":"Macarol","year":"1994","unstructured":"Macarol V, Fraunfelder FT (1994) Pamidronate disodium and possible ocular adverse drug reactions. Am J Ophthalmol 118 (2):220\u2013224","journal-title":"Am J Ophthalmol"},{"key":"1986_CR36","first-page":"49","volume":"43","author":"Salmen","year":"2002","unstructured":"Salmen S, Berrueta L, Sanchez N, Montes H, Borges L (2002) Nongranulomatous anterior uveitis associated with alendronate therapy. Invest Clin 43(1):49\u201352","journal-title":"Invest Clin"},{"key":"1986_CR37","first-page":"837","volume":"117","author":"Mbekeani","year":"1999","unstructured":"Mbekeani JN, Slamovits TL, Schwartz BH, Sauer HL (1999) Ocular inflammation associated with alendronate therapy. Arch Ophthalmol 117(6):837\u2013838","journal-title":"Arch Ophthalmol"},{"key":"1986_CR38","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJM200303203481225","volume":"348","author":"Fraunfelder","year":"2003","unstructured":"Fraunfelder FW, Fraunfelder FT (2003) Bisphosphonates and ocular inflammation. N Engl J Med 348(12):1187\u20131188","journal-title":"N Engl J Med"},{"key":"1986_CR39","unstructured":"Springuel P, McMorran M (2003) Bisphosphonates and ocular disorders; Canadian Adverse Drug Reaction Newsletter. Canada, Health Canada. Pamphlet"},{"key":"1986_CR40","doi-asserted-by":"crossref","unstructured":"Shakir SAW (2002) PEM in the UK. In: Mann RD, Andrews EB (eds) Pharmacovigilance. Wiley pp\u00a0333\u2013344","DOI":"10.1002\/0470853093.ch26"},{"key":"1986_CR41","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2165\/00002018-199819030-00001","volume":"19","author":"Venulet","year":"1998","unstructured":"Venulet J, Bankowski Z (1998) Harmonizing adverse drug reaction terminology: the role of the Council for International Organizations of Medical Sciences. Drug Saf 19(3):165\u2013172","journal-title":"Drug Saf"},{"key":"1986_CR42","unstructured":"Shakir SA (2004) Causality and correlation in pharmacovigilance. In: Talbot PWJ (ed) Stephens\u2019 detection of new adverse drug reactions. Wiley, Chichester, UK, pp 329\u2013343"},{"key":"1986_CR43","unstructured":"CIOMS.WHO (1993) International guidelines for biomedical research involving human subjects. CIOMS WHO, Geneva"},{"key":"1986_CR44","unstructured":"Royal College of Physicians of London (1996) Guidelines on practice of ethical committees in medical research involving human subjects. Royal College of Physicians of London, pp\u00a01\u20138"},{"key":"1986_CR45","first-page":"21","volume":"C","author":"Multi-Centre","year":"2000","unstructured":"Multi-Centre Research Ethics Committee (2000) Guidance notes. Examples of enquiries and surveys in the public interest where no reference to a research ethics committee is necessary. Appendix C:21","journal-title":"Appendix"},{"key":"1986_CR46","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/S0140-6736(01)06898-2","volume":"358","author":"Heeley","year":"2001","unstructured":"Heeley E, Riley J, Layton D, Wilton LV, Shakir SA (2001) Prescription-event monitoring and reporting of adverse drug reactions. Lancet 358(9296):1872\u20131873","journal-title":"Lancet"},{"key":"1986_CR47","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1136\/bmj.313.7059.732","volume":"313","author":"McAvoy","year":"1996","unstructured":"McAvoy BR, Kramer EF (1996) General practice postal surveys: a questionnaire too far? BMJ 313(7059):732\u2013733","journal-title":"BMJ"},{"key":"1986_CR48","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00198-003-1399-y","volume":"14","author":"Biswas","year":"2003","unstructured":"Biswas PN, Wilton LV, Shakir SA (2003) Pharmacovigilance study of alendronate in England. Osteoporos Int 14:507\u2013514","journal-title":"Osteoporos Int"},{"key":"1986_CR49","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1023\/A:1005574009856","volume":"45","author":"Lichtenberger","year":"2000","unstructured":"Lichtenberger LM, Romero JJ, Gibson GW, Blank MA (2000) Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa. Dig Dis Sci 45(9):1792\u20131801","journal-title":"Dig Dis Sci"},{"key":"1986_CR50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","volume":"14","author":"Hamilton","year":"2003","unstructured":"Hamilton B, McCoy K, Taggart H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14(3):259\u2013262","journal-title":"Osteoporos Int"},{"key":"1986_CR51","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1046\/j.1365-2036.2000.00816.x","volume":"14","author":"Blank","year":"2000","unstructured":"Blank MA, Gibson GW, Myers WR, Dierckman TA, Phipps RJ, Smith PN (2000) Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH. Aliment Pharmacol Ther 14(9):1215\u20131223","journal-title":"Aliment Pharmacol Ther"},{"key":"1986_CR52","unstructured":"WHO Collaborating Centre for International Drug Monitoring (2002) Caveat document, accompanying statement to data released from the WHO Collaborating Centre. 1. WHO Collaborating Centre for International Drug Monitoring, Uppsala, Sweden"},{"key":"1986_CR53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre S, Lansner A, De Freitas RM (1998) A Bayesian neural network method for adverse drug reaction signal generation . Eur J Clin Pharmacol 54:315\u2013321","journal-title":"Eur J Clin Pharmacol"},{"key":"1986_CR54","unstructured":"Summary of product characteristics (2005) Actonel 5\u00a0mg. Procter and Gamble Pharmaceuticals UK, pp\u00a01\u20138"},{"key":"1986_CR55","unstructured":"Summary of product characteristics (2005) Actonel 30\u00a0mg. Procter and Gamble Pharmaceuticals UK, pp\u00a01\u20136"},{"key":"1986_CR56","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1006\/rtph.2002.1550","volume":"35","author":"Steinbuch","year":"2002","unstructured":"Steinbuch M, D\u2019Agostino RB, Mandel JS, Gabrielson E, McClung MR, Stemhagen A, Hofman A (2002) Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol 35(3):320\u2013326","journal-title":"Regul Toxicol Pharmacol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-005-1986-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-005-1986-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-005-1986-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T09:34:00Z","timestamp":1683192840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-005-1986-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,31]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["1986"],"URL":"https:\/\/doi.org\/10.1007\/s00198-005-1986-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,31]]}}}